● Senti's lead candidate, SENTI-202, is a gene-circuit CAR-NK cell therapy aimed at relapsed or refractory acute myeloid leukemia.
Tvardi Therapeutics (NASDAQ:TVRD) is at the stage every clinical biotech must eventually reach: the point where pipeline promise meets the hard arithmetic of cash and catalysts. The company, which develops orally available small-molecule STAT3 inhibitors, updated investors in mid-August 2026 with aBusinessreview that laid …
● The company reaffirmed its 2026 and 2027 guidance.
HCW Biologics (NASDAQ:HCWB) is an immunotherapy company developing novel biologics aimed at chronic inflammation and autoimmune diseases. The company reported second-quarter 2026 results with an update on an early-stage program, following a period of building progress.
Keros Therapeutics (NASDAQ:KROS) has undergone a wrenching reset, discontinuing development of a lead cardiopulmonary drug after safety concerns and restructuring around a different candidate. Understanding what the company is now focused on, and what it discontinued, is essential to assessing the shares.
MoonLake Immunotherapeutics (NASDAQ:MLTX) has been generating the kind of late-stage clinical data that can define a biotech's future, reporting positive Phase 3 results for its lead drug across multiple inflammatory diseases. With a differentiated therapy and a string of successful trials, investors are watching …
● The company reported 30-day results from the CGUARDIANS II clinical trial of its CGuard Prime implant.
●Phase 3 trial underway:PDS Biotechnology is running the VERSATILE-003 trial evaluating its Versamune HPV immunotherapy in HPV16-positive head and neck cancer.
●Positive extension data:Reviva reported a full dataset from a one-year Phase 3 RECOVER open-label extension study evaluating brilaroxazine in schizophrenia.
Skye Bioscience (NASDAQ:SKYE) is positioning itself for a bigger role in the crowded obesity-drug arena, and a mid-August 2026 transaction has given the effort freshCapitaland a new strategic dimension. The clinical-stage company, whose lead program targets a novel mechanism for weight management, announced a …